Each retrieved citation was reviewed by two independently working reviewers. Most articles were excluded on the basis of information provided by the title or abstract. Citations that appeared to be appropriate or those that could not be excluded unequivocally from the title and abstract were identified, and the corresponding full text reports were reviewed by the two reviewers. Any disagreement between them was resolved by reviewer consensus. From the included articles, the following data were extracted: patient demographics, preexisting diagnosis, instability, treatment, follow-up, fusion rate, symptoms, and change in symptoms.
formed considering the following AHRQ required and additional domains.
4 ►Table 7 provides an outline of the method used to determine the final strength of evidence (SoE).
• Risk of bias is evaluated during the individual study evaluation described above. After individual article review, the literature evidence was rated as "HIGH" initially if the majority of the articles are Level I or II. It is rated as "LOW" if the majority were level III or lower. This is the "baseline" SoE, ►Table 7. The consistency, directness, precision, and subgroup effects are considered for potential "downgrading" the strength of the body of evidence (one or two levels depending on the degree and number of domain violations). • C7 radicular pain: 12% (2/17) • C5 palsy: 6% (1/17)
• Restenosis at C3-C7: 6% (1/17)
• Shoulder numbness or pain: 12% (2/17)
• Infection at surgical site: 6%
(1/17)
• CDH, cervical disc herniation; CoE, class of evidence; CSM, cervical spondylotic myelopathy; f/u, follow-up; NR, not reported; OPLL, ossification of posterior longitudinal ligament; RCT, randomized controlled trial. JOA, Japanese Orthopedic Association score; evaluation of the neurological function of patients with cervical myelopathy; range of score 0-17 points, with a lower score indicating a poor outcome. JOA recovery rate ¼ 100% (postoperative JOA score -preoperative JOA score) / (17-preoperative JOA score).
Nurick score: evaluates severity of myelopathy; range of score 0-5, with higher scores indicating greater severity. SF-36: short form 36 health survey questionnaire; measures physical functioning, limitations in usual role of activities resulting from physical health problems, bodily pain, general health perceptions, vitality, social functioning, limitations in usual role activities because of emotional problems, and mental health; range of score 0-100, with a lower score indicating a poor outcome.
VAS reported on 0-100 mm scale, with higher score indicating maximum pain.
a Study also included a third intervention group, Z-plasty (n ¼ 35) (Naito, 1994) .
b JOA recovery rates defined as: excellent (75-100%), good (50-74%), fair (20-49%), and poor (< 20%) (Naito, 1994).
c Some patients experienced multiple adverse events (Okada, 2009); study reports reoperation (anterior cervical fusion) for 2 patients following pseudarthrosis, but it is unclear which type of cervical laminoplasty these patients received (Naito, 1994). Comparative Effectiveness of Different Types of Cervical Laminoplasty Heller et al.
Criteria Evaluated for "Downgrading"
• Consistency refers to the degree of similarity in the effect sizes of different studies within an evidence base. If effect sizes indicate the same direction of effect and if the range of effect sizes is narrow, an evidence base was judged to be consistent. If meta-analyses were conducted, we evaluated the consistency with an "eye ball test." This test consists of a visual appraisal of the forest plots by two independent reviewers. Single study evidence bases were judged "consistency unknown (single study)" and downgraded.
• Directness is concerned with whether the evidence being assessed reflected a single, direct link between the interventions of interest and the ultimate health outcome; that is, a determination of whether the most clinically relevant outcome was measured or if a surrogate outcome was assessed. Directness also applies to indirect comparisons of treatment when head to head comparisons of interest could not made within individual studies.
• Precision of evidence pertains to the degree of certainty surrounding an estimate of effect for a specific outcome. This is based on whether the estimate of effect reached statistical significance and/or the inspection of confidence intervals around effect estimates. When there are only two subgroups, the overlap of the confidence intervals of the summary estimates of the two groups is considered. No Blank cells indicate that the criterion was either not met or that it could not be determined. overlap of the confidence intervals indicates statistical significance, but the confidence intervals can overlap to a small degree and the difference still is statistically significant.
• Subgroup effects. For evaluating subgroup effects (i.e., heterogeneity of treatment effects), we downgrade if the authors do not state a priori their plan to perform sub-group analyses and if there was no test for interaction. Outcome assessment is independent of health-care personnel judgment. Reliable data are data such as mortality or re-operation. b Authors must provide a description of robust baseline characteristics, and control for those that are unequally distributed between treatment groups. Table 7 Methodology outline for determining overall strength of evidence (SoE)
All AHRQ "required" and "additional" domainsa are assessed. Only those that influence the baseline grade are listed in Criteria used for "Upgrading"
• Finally, if the SoE is less than "HIGH," we "upgrade" the evidence if there is a dose-response association or a strong magnitude of effect.
Strength of Evidence for Existing Systematic Reviews
Level of evidence ratings for Cochrane reviews and other systematic reviews are assigned a baseline score of HIGH if RCTs were used, LOW if observational studies were used. The rating can be upgraded or downgraded based on adherence to the core criteria for methods, qualitative, and quantitative analyses for systematic reviews (there is a reference/evaluation table for this).
The following four possible levels and their definition are reported:
• High: High confidence that the evidence reflects the true effect. Further research is very unlikely to change our confidence in the estimate of effect.
• Moderate: Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.
• Low: Low confidence that the evidence reflects the true effect. Further research is likely to change the confidence in the estimate of effect and likely to change the estimate.
• Insufficient: Evidence either is unavailable or does not permit a conclusion.
